Evidence map›Paper›PMID 28728606›Full record

Trial reportArthritis research & therapy2017

Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study.

Johanne Martel-Pelletier, Jean-Pierre Raynauld, François Mineau, François Abram, Patrice Paiement, Philippe Delorme, Jean-Pierre Pelletier

2 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Arthritis research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01354145 phase3completednot on this map

Twenty-four Month Exploratory Study of the Effect of Chondroitin Sulphate on Structural Changes in Knee Osteoarthritis Patients as Assessed by MRI

TypeinterventionalSponsorBioibericaRan2011 to 2014Enrolled194ConditionsKnee OsteoarthritisArmsChondroitin sulfate, Celecoxib
NCT07494838 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

IMAGES: Identifying Metabolic Imaging Association With Genicular Artery Embolization Success

TypeinterventionalSponsorLucas R. Cusumano, MDRan2026 to 2027Enrolled25ConditionsKnee Osteoarthritis, Knee Discomfort, Knee Pain Chronic, Knee Swelling PainArmsEmbolization
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Heterologous production of chondroitin.Biotechnology reports (Amsterdam, Netherlands) · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. [Mechanism of high expression of high mobility group protein 1 in a rat model of knee osteoarthritis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021
    Article
  11. Review
  12. Article
  13. From Pathogenesis to Therapy in Knee Osteoarthritis: Bench-to-Bedside.International journal of molecular sciences · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Johanne Martel-PelletierOsteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), 900 Saint-Denis, Suite R11.412, Montreal, Quebec, H2X 0A9, Canada.
Jean-Pierre RaynauldOsteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), 900 Saint-Denis, Suite R11.412, Montreal, Quebec, H2X 0A9, Canada.
François MineauOsteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), 900 Saint-Denis, Suite R11.412, Montreal, Quebec, H2X 0A9, Canada.
François AbramMedical Imaging Research & Development, ArthroLab Inc, Montreal, Quebec, Canada.
Patrice PaiementArthroLab Inc, Montreal, Quebec, Canada.
Philippe DelormeArthroLab Inc, Montreal, Quebec, Canada.
Jean-Pierre PelletierOsteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), 900 Saint-Denis, Suite R11.412, Montreal, Quebec, H2X 0A9, Canada. dr@jppelletier.ca.
Centre Hospitalier de l’Université de Montréal · CAUniversité de Montréal · CAPerkinElmer Biosignal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is an obvious need to identify biomarkers that could predict patient response to an osteoarthritis (OA) treatment. This post hoc study explored in a 2-year randomized controlled trial in patients with knee OA, the likelihood of some serum biomarkers to be associated with a better response to chondroitin sulfate in reducing cartilage volume loss.

methodsEight biomarkers were studied: hyaluronic acid (HA), C reactive protein (CRP), adipsin, leptin, N-terminal propeptide of collagen IIα (PIIANP), C-terminal crosslinked telopeptide of type I collagen (CTX-1), matrix metalloproteinase-1 (MMP-1), and MMP-3. Patients were treated with chondroitin sulfate (1200 mg/day; n = 57) or celecoxib (200 mg/day; n = 62). Serum biomarkers were measured at baseline. The cartilage volume at baseline and its loss at 2 years were assessed by quantitative magnetic resonance imaging (MRI). Statistical analysis included analysis of covariance.

resultsAs data from the original MOSAIC trial showed no differences in cartilage volume and loss in the lateral compartment of the knee joint between the two treatment groups in any comparison, only the medial compartment and its subregions were studied. Stratification according to the median biomarker levels was used to discriminate treatment effect. In patients with levels of biomarkers of inflammation (HA, leptin and adipsin) lower than the median, those treated with chondroitin sulfate demonstrated less cartilage volume loss in the medial compartment, condyle, and plateau (p ≤ 0.047). In contrast, patients treated with chondroitin sulfate with higher levels of MMP-1 and MMP-3, biomarkers of cartilage catabolism, had less cartilage volume loss in the medial compartment, condyle, and plateau (p ≤ 0.050). Patients with higher levels of PIIANP and CTX-1, biomarkers related to collagen anabolism and bone catabolism, respectively, had reduced cartilage volume loss in the medial condyle (p ≤ 0.026) in the chondroitin sulfate group.

conclusionThis study is suggestive of a potentially greater response to chondroitin sulfate treatment on cartilage volume loss in patients with knee OA with low level of inflammation and/or greater level of cartilage catabolism.

trial registrationThis is a post hoc study. Original trial registration: ClinicalTrials.gov, NCT01354145 . Registered on 13 May 2011.

Indexed as

AdultAgedBiomarkersCartilage, ArticularCelecoxibChondroitin SulfatesCyclooxygenase 2 InhibitorsDouble-Blind MethodFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedOsteoarthritis, KneeTreatment OutcomeBiomarkersCelecoxibChondroitin SulfatesCyclooxygenase 2 InhibitorsBiomarkersClinical trialKneeOsteoarthritis

Identifiers

PMID28728606
PMCPMC5520291
OpenAlexW2738160056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.